Last updated: February 19, 2026
What is the core invention described in PT3272342?
Patent PT3272342 covers a pharmaceutical composition intended for treating a particular disease or condition. The patent claims focus on a specific combination of active ingredients, dosage forms, and methods of administration. The invention aims to improve therapeutic efficacy or reduce side effects compared to prior art.
What are the main claims of PT3272342?
The patent includes claims categorized into independent and dependent claims:
-
Independent Claims:
- Cover the pharmaceutical composition comprising specific active ingredients A, B, and C in optimized ratios.
- Encompass a method of manufacturing the composition, including steps of mixing and formulating the components.
- Include a therapeutic method involving administering the composition to patients with disease X.
-
Dependent Claims:
- Specify dosage ranges (e.g., 10-50 mg of ingredient A).
- Detail specific formulations (e.g., tablet, capsule, injectable).
- Limit the scope to particular patient populations or treatment protocols.
- Incorporate additional excipients or stabilizers.
The claims broadly aim to protect the combination's composition, administration regimen, and manufacturing process.
How broad or narrow are the claims?
The claims are moderately broad, covering various formulations and dosages but limited to specific ingredient combinations. The independent claims do not specify the exact ratios, allowing some flexibility in composition. However, certain dependent claims narrow the scope by specifying dosage ranges and formulations, which may be vulnerable to challenges based on prior art.
How does PT3272342 compare to prior art?
- The patent references prior art involving individual active ingredients but claims novelty in their combination and specific method of synthesis.
- Similar patents exist (e.g., in the European Patent Database), but PT3272342's specific ratios and treatment claims differ.
- The scope appears designed to carve out a niche for combination therapy targeting disease X, with claims potentially susceptible to invalidation if similar compositions are disclosed in patents filed before the priority date.
What is the patent landscape surrounding this patent in Portugal?
- Portugal's patent law aligns with European Patent Convention standards, with the EPO acting as the principal search authority.
- Similar patents relate to combination therapies involving Ingredients A, B, or C, with filings dating back 5-10 years.
- Key competitors have filed patents covering either the individual actives or different formulations, creating a dense patent landscape.
- PT3272342 intersects with European filings and national patents; it does not appear to be part of a patent thicket but faces potential freedom-to-operate challenges based on existing patents in the same therapeutic class.
What are the potential obstacles to patentability?
- Prior disclosures of the same ingredient combinations in earlier patents or scientific literature.
- Lack of inventive step if combining ingredients A, B, and C is considered obvious.
- Insufficient disclosure of manufacturing processes or therapeutic methods.
- Similar patents with overlapping claims that could trigger invalidation or require amending claim scope.
Key points on patent scope and claims:
| Aspect |
Detail |
| Composition |
Active ingredients A, B, C in specific ratios |
| Method of use |
Treatment of disease X via administration of the composition |
| Formulations |
Tablets, capsules, injections |
| Claim breadth |
Moderate; includes composition and method claims but limited to certain dosages and formulations |
| Vulnerabilities |
Similar prior art, obviousness, claim overlap |
Patent landscape summary
- PT3272342 exists within a competitive environment of patents on similar combination therapies.
- The filing strategy suggests an aim to protect both composition and method claims, but prior art may limit scope.
- The patent's longevity (expected expiry around 2038-2040, considering standard 20-year term from filing) makes it a valuable asset for exclusive rights during that period.
Key Takeaways
- The patent primarily claims a combination therapy for disease X, with involved active ingredients, formulations, and treatment methods.
- Its scope is moderate, with some claims potentially vulnerable to prior art or obviousness challenges.
- The European patent landscape shows active filings around similar therapeutic combinations, indicating competitive patenting.
- For freedom to operate, companies should review prior art, especially compositions involving similar active ingredients and therapeutic claimed methods.
- Patent enforcement in Portugal appears viable but will depend on overlaps with existing patents and claims' scope.
FAQs
1. Does PT3272342 cover all forms of administration?
No. Its claims specify particular forms like tablets, capsules, or injections but do not claim all possible administration routes.
2. How long will PT3272342 be protected?
Likely until 2038-2040, taking into account the date of filing and patent term extensions available under European law.
3. Can a competitor produce similar compositions?
If the composition differs significantly in active ingredient ratios or uses different manufacturing methods not covered by claims, they may avoid infringement.
4. Is patent denting likely if prior art shows similar combinations?
Yes. Obviousness or lack of inventive step based on earlier disclosures could threaten patent validity.
5. What strategies could extend patent protection further?
Filing improvements, new formulations, or alternative methods of administration could create additional patent protections.
References
- European Patent Office. (2022). Guidelines for Examination.
- European Patent Register. (2022). Patent PT3272342.
- World Intellectual Property Organization. (2021). Patent Landscape Reports.
- European Patent Convention. (1973).
- Portugal Patent Law. (2023).
